A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

Updated on 10 May 2022
advanced cancer


The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies.

This investigational intervention treatment uses a single biological drug and is conducted in two parts.

  • Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. 
  • Part 2: INCAGN02390 administered Q2W or Q4W at the recommended dose(s) from Part 1.




Condition Mesothelioma, Non-Small Cell Lung Cancer, Head and Neck Cancer Cervical Cancer Gastric Cancer Stomach Cancer Gastroesophageal Junction Cancer Esophageal Cancer Hepatocellular Carcinoma Melanoma Uveal Melanoma Merkel Cell Carcinoma Mesothelioma MSI NSCLC Ovarian Cancer Squamous Cell Carcinoma of the Head and Neck Small Cell Lung Cancer Renal Cell Carcinoma RCC Triple-negative Breast Cancer Urothelial Carcinoma Mismatch Repair Deficiency
Clinical Study IdentifierTX218264
Last Modified on10 May 2022


Yes No Not Sure

Inclusion Criteria

Participants with locally advanced or metastatic tumors who are not eligible for any available therapy likely to convey clinical benefit (locally advanced disease must not be amenable to resection with curative intent)
Participants who have disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment
Willingness and ability to safely undergo pretreatment and on-treatment tumor biopsies (core or excisional)
Eastern Cooperative Oncology Group performance status 0 or 1
Willingness to avoid pregnancy or fathering children based on protocol-defined criteria

Exclusion Criteria

Laboratory values at screening outside the protocol-defined ranges
Administration of colony-stimulating factors within 14 days before Study Day 1
Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug
Receipt of a live vaccine within 30 days of planned start of study drug
Note: Examples of live vaccines include, but are not limited to, the
following: measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies
Bacillus Calmette-Guerin, and typhoid vaccine. Seasonal influenza vaccines for
injection are generally killed virus vaccines and are allowed; however
intranasal influenza vaccines are live-attenuated vaccines and are not
Active autoimmune disease that required systemic treatment in the past (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)
Known active central nervous system metastases and/or carcinomatous meningitis
Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for > 1 year, after treatment with curative intent
Evidence of active, noninfectious pneumonitis or history of interstitial lung disease
Active infection requiring systemic therapy
Evidence of active HBV or HCV infection
Known history of HIV (HIV 1/2 antibodies)
Known allergy or reaction to any component of study drug or formulation components
Prior treatment with an anti-TIM-3 antibody for any indication
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note